SABI Mind

You’re invited to experience the SABI Mind philosophy and meet the team of talented experts from the Calgary clinic.

Get a first-hand look at the Calgary Healing Centre and have the opportunity to learn more about psychedelic-assisted therapies from the team of mental health and chronic pain specialists.

Feel free to stop in at the clinic with a guest. Light refreshments and snacks will be served.

When: November 23, 3:00pm - 6:00pm MST

Where: SABI Mind Calgary Clinic: Suite 202, 1615 10 Ave SW.

RSVP at the link in bio

Curious about Ketamine-Assisted Psychotherapy?

Want to know if you might benefit from our treatments?

Our team of physicians, therapists, and clinic staff is devoted to helping clients experience the beauty of mending in a safe therapeutic setting that optimizes the psychedelic experience. ⁠ ⁠

At SABI, you may safely explore your psyche, address the roots of suffering and trauma, and feel supported in integrating the resulting insights into your daily life in a structured way. ⁠

Book your consultation with our Experience Specialist and start your journey today.

link in our bio

https://www.sabimind.com/book-a-consultation

Get your tickets for the upcoming MAPSCANADA webinar on Thursday, October 6th, 2023. This event will feature a panel of speakers, including SABI Mind President Philippe Lucas, PhD discussing Balancing Safety and Access: Cost Coverage for Psychedelic-Assisted Care.

Learn about the state of cost coverage for psychedelic-assisted care in Canada, the impact on patients paying out of pocket and more. Tickets are available at the link below.

Balancing Safety and Access: Cost Coverage for Psychedelic-Assisted Care Affordability greatly impacts patient access to psychedelic-assisted care. Join us in a conversation about options for cost-coverage.

PsyCan recently released its 2023 white paper urging the Federal Government to look beyond the Special Access Program in regulating psychedelic substances.

PsyCan Vice-Chair, White Paper Committee Chair, and SABI Mind president Dr. Philippe Lucas Ph.D., said: “The Canadian healthcare system is based on the principle of patient and physician autonomy in making fundamental decisions about medical treatments. However, most psychedelic-assisted therapies are an exception to this – requiring individual federal government approval on a per-patient basis,”

You can follow the link below to read the full paper.

PsyCan - White Paper PsyCan — the not-for-profit trade association of legally-operating Canadian psychedelic companies — is pleased to share its 2023 White Paper on the future of psychedelic access in Canada: Beyond the Special Access Program — Regulatory Analysis and Recommendations on Psychedelic Access in Canad...